Novartis firm AveXis gets EC nod for Zolgensma to treat spinal muscular atrophy

This article was originally published here

The approval allows Zolgensma to treat patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1or patients with

The post Novartis firm AveXis gets EC nod for Zolgensma to treat spinal muscular atrophy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply